Scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria. Tuberculosis (TB) bacteria infect a third of the world’s population and the disease kills 1.8 million people annually.